

(AVAREF): ROLE IN RESEARCH AND **INNOVATION**

Kwasi Nyarko (PhD) Chinwe Iwu-Jaja (PhD) **AVAREF Secretariat Brazzaville**

African Region







Four points to be covered...

Global Health Context

Overview of AVAREF

AVAREF: Role in Vaccine Research and Innovation

Key messages





Global Health Context

- Biomedical research in Africa has surged in the past decade
- A regulatory platform is needed to improve expertise, access to therapies, and regulatory efficiency
- Regulatory efficiency is critical





OVERVIEW OF AVAREF A Network of 55 member countries





Overview of the African Vaccines Regulatory Forum (AVAREF)



Established as an informal network 17 years ago by WHO



A Vision of An African population with timely access to safe and efficacious medical products of assured quality.



Uses a network approach (driven my member states) to build technical/scientific expertise, competence, and skills required to support regulatory decision making.



Capacity building and training in member countries for both NRAs and NECs including clinical trial optimization exercises...



Collaborating effectively with several partners and stakeholders including AU agencies such as AUDA-NEPAD, US-FDA, European Medicines Agency, German Paul Ehrlich...

National Immunization strategies





African Vaccine regulatory Forum (AVAREF)

- The African Vaccine Regulatory Forum (AVAREF), a network of National Regulatory
 Authorities (NRAs) and Ethics Committees (ECs).
- Established in 2006 by the WHO to build capacity & improve the harmonization of practices in support of product development.
- Help NRAs, ECs, and sponsors to achieve consensus on regulatory and ethics questions surrounding R&D of medical products.

AVAREF Objectives

To increase the efficiency and quality of reviews and inspections and the timeliness and transparency of regulatory decisions for all interventional trials conducted in Africa

To promote patient safety

To accelerate the African Medicines Regulatory Harmonization (AMRH) process, linking all Regional Economic Communities (RECs)

To stimulate innovation and research in Africa

To enhance emergency preparedness on the continent, in RECs and in individual countries





AVAREF Renewed Context



Emerging ecosystem which is complex, dynamic, and in its infancy hence requires a renewed approach towards effective capacity building for results and impacts

Effective interactions required from the involvement of multiple actors from multiple sectors within the emerging ecosystem

AVAREF has a Renewed Strategic Approach based on 4 Reinforcing Pillars of Action

An urgent need for innovation and real results for Africa





AVAREF 4 Pillars for Excellence in Capacity Building

Excellence in Capacity Building

Training Regulatory Reviewers – Fundamental & Specialized

Training for ethics reviewers as well as effective synchronization of ethics reviews with regulatory reviews

Multi-Country Joint Review of Clinical Trial Applications (CTAs)

Regulatory Harmonization – Tools, Guidelines, Framework development

Partnerships and Alliances for Results

African Union Organizations
AfricaCDC, AUDA-NEPAD

Competent International Regulatory Agencies and Institutions

Donors, Development Partners such as BMGF, Wellcome Trust, GAVI, etc

Trusted Expertise -Specialized and/or Technical Support

Emergency Registration of Medicines such as Covid-19 Vaccines, Ebola Vaccines, Malaria Vaccines, etc.

Rosters of Expertise to support NRAs, NECs, and realization of African Medicines Agency

Technical Committees for Clinical Trials and Pharmacovigilance

Life Cycle Approach

Regulatory and
Ethics Involved in all
aspects of Innovation
cycle from design,
research,
commercialization,
regulation, product
registration, post
authorization s





A Strong Record of AVAREF Capacity Building Activities

Multi-Country Joint Activities

Scientific Advice for Clinical Trials

Multi-Country Joint Review of Clinical Trial Applications (CTAs)

Emergency Registration of Medicines such as Covid-19 Vaccines, Ebola Vaccines, Malaria Vaccines, etc.

Country Support

Training of staff in review of life cycle of products; clinical trials, GXPs – GCP, GLP, GMP, GRPs.

Training for ethics reviewers as well as effective synchronization of ethics reviews with regulatory reviews

Optimization Exercises such as for clinical trial authorization

Harmonization

Technical Committees for development of guidelines, check lists and guidance documents

Advisory Committee setting workplans, adoption of developed guidelines and tools

Adoption and implementation of AVAREF Tools and Guidelines





AVAREF Achievements

Extensive contribution to regulatory harmonization through the development of tools and guidelines which have been adopted by over 26 member states

AVAREF has supported authorization several multi-country clinical trial applications for neglected diseases such as Monkeypox, Lassa fever, and Rift Valley Fever

AVAREF has used its platform in emergencies for the authorization of clinical trials as well as registration of products such as Ebola, Covid-19, Malaria vaccine, etc.

Active calendar of events including regular webinars, country support, etc.





AVAREF Achievements

Extensive contribution to regulatory harmonization through the development of tools and guidelines which have been adopted by over 26 member states

AVAREF has authorized several multi-country clinical trial applications for neglected diseases such as Monkeypox, Lassa fever, and Rift Valley Fever

AVAREF has used its platform in emergencies for the authorization of clinical trials as well as registration of products such as Ebola, Covid-19, Malaria vaccine, etc.

Active calendar of events including regular webinars, country support, etc.





AVAREF Platform used to facilitate emergency registration of COVID-19 vaccines 2021-2022

























AstraZeneca AZD1222 & Covishield

25 February 2021

15 countries



Ad26.COV2.S

8 April 2021

23 countries



Moderna mRNA-1273

24 May 2021 13 countries

16 June 2021

~20 countries



30 June 2021

~17 countries



Pfizer/BioNTech CoronaVac (in preparation)

23 July 2021

~19 countries



Novavax Covavax & Nuvaxovid

17 February 2022 All countries

Bharat Covaxin

17 February 2022 All countries



Janssen Zabdeno & Mvabea Ebola vaccines

May 24, 2022 ~ 15 countries



Merck Ebola vaccine

~ 24 July 2022 All countries **CanSino Biologics** Inc.

CONVIDECIA COVID-19 Vaccine, (Ad5.CoV2-S [Recombinant])

July 2022 All countries





AVAREF: Role in Vaccine Research and Innovation





Vaccine Safety is of Paramount Importance

Disease prevention

Vaccines are given to **prevent** disease, this limits the tolerability of adverse events → risk/benefit assessment.

Risk benefit assessment

Vaccines are given to **healthy population** hence the risk benefit assessments are different from that of other medicines; hence the risk tolerance is very low.

Regulatory oversight key

Vaccines are administered to **large cohorts** of **healthy** infants and adults → enhanced regulatory oversight required





AVAREF's Role in Vaccine Research and Innovation

Use of Platform and network of National Regulatory Agencies, National Ethics Committee, and Institutional Review Boards for Clinical Trials as the basis of a network approach to Vaccine Research and Innovation

Establish network of major clinical trials and principal investigators involved in vaccine research for identification of research challenges, identification of research priorities, research gaps, and generation of potential solutions

Establish a Continental Expert Working Group on Vaccine Research and Innovation to guide the setting of a capacity building agenda as well as development of a strategic business and operational plan for action

- Mechanisms for identification or practical continental research priorities
- Mechanisms for stable funding for research and accountability

Building and developing a coalition of partners to drive the agenda for research innovation in the vaccine ecosystem in Africa





AVAREF's Role in Vaccine Research and Innovation (2)

Researcher capacity building geared towards increasing African-led or inspired internationally funded research proposals.

Platform for interface between Researchers, Industry, and Investors (Donors)

- Best practices in research Good Research Designs, Informativeness, Statistical Support, etc.
- Training in writing effective grant proposals to be competitive in international granting marketplace

Use of a life-cycle approach for vaccine research and innovation

- Fostering vaccine research to enrichen the ecosystem to support innovation
- Support for commercialization, patent protection
- Effective policy support for the research enterprise in Africa

Facilitating access to expertise, mentorship, and partnerships with major international research institutions interested in diseases of interest to Africa





Strategic Priorities of AVAREF Vaccine Research and Innovation

Develop/Expand partnerships and/or alliances to facilitate delivery of results

Development (and delivery) of enhanced technical/scientific training and capacity building activities to support vaccine researchers in Africa

Promote research and innovation in Africa to enrichen the ecosystem that supports biotherapeutics, including vaccines.

Support the establishment of a dynamic Vaccine Research Network based on the AVAREF network model









Key messages



The level and extent of research and innovation in Africa is significantly lower than required and there is tremendous opportunities for growth



A need for all parties to enhance (ramp-up) its activities (approaches) to ensure that untapped resources ranging from talent of the scientist to untapped genetic diversity is harnessed for the production innovative products for global use



Establishment of a platform for the global research needs to be presented so that African researchers can effectively contribute has the potential to be a global game changer, especially when researchers meet industry and users of research results.



Life cycle approach required to ensure viability of the vaccine research ecosystem in Africa. Hence efforts should be along the innovation life cycle from design to product licensing, use, and disposal.



WHO (AVAREF) committed to use its network approach, experience, and ability to bring multiple stakeholders together to strengthen the technical capacity for this initiative.



Contact AVAREF:



Dr Kwasi Nyarko: nyarkok@who.int

AVAREF Coordinator WHO Regional Office for Africa

Dr Chinwe Iwu-Jaja: iwujajac@who.int
Technical officer, AVAREF
WHO Regional Office for Africa









